相关临床试验
10
8 进行中
药物批准
7
批准总数
监管机构
1
监管机构数
成立时间
2010
进行中（未招募）
8
80.0%
Unknown
2
20.0%
- NICE has issued final draft guidance recommending mirdametinib (Ezmekly) for symptomatic plexiform neurofibromas associated with neurofibromatosis type 1 (NF1) in patients aged two to 17. - The recommendation extends drug treatment access to children as young as two for the first time, versus the prior age-three threshold for selumetinib (Koselugo). - Clinical evidence indicates mirdametinib can reduce tumour size with outcomes at least comparable to, and potentially better than, existing options, though based on indirect comparisons. - The oral MEK inhibitor, administered twice daily as a tablet or dissolvable liquid, is manufactured by Merck Serono and will require NHS funding within 30 days of formal publication.
- Northwest Biotherapeutics has appointed Dr. Annalisa Jenkins, a distinguished biopharma leader with over 25 years of experience, as Strategic Adviser to advance its DCVax® dendritic cell-based cancer vaccine platform. - The company's lead program DCVax®-L for glioblastoma has completed a 331-patient Phase III trial and submitted a Marketing Authorization Application to the UK's MHRA for commercial approval. - The DCVax® platform is designed to address solid tumors, which represent approximately 90% of all cancers, with clinical trials encompassing 16 diverse tumor types. - Dr. Jenkins brings extensive expertise from executive roles at major pharmaceutical companies including Merck Serono and Bristol-Myers Squibb, plus experience as CEO of gene therapy company Dimension Therapeutics.
- Sandoz creates a dedicated global biosimilar development, manufacturing and supply unit led by industry veteran Armin Metzger to capitalize on the upcoming "golden decade" of biosimilar opportunities. - The company announces a major partnership with Samsung Bioepis for up to five biosimilar assets, starting with vedolizumab, potentially expanding its pipeline to 32 assets. - These strategic moves position Sandoz to capture a significant share of the projected USD 320 billion biosimilar loss-of-exclusivity market opportunity over the next decade.
- Merck Serono and Quintiles establish an innovative five-year clinical development agreement, marking the first strategic collaboration of its kind between a biopharma company and services provider. - The partnership aims to accelerate therapeutic development across neurology, oncology, immuno-oncology, and immunology, with Quintiles becoming Merck's exclusive clinical development services provider. - Under the agreement, Merck Serono will lead strategic direction while Quintiles manages clinical trial execution, spanning from phase 1 through post-marketing studies.
